- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Actinium Pharmaceuticals Inc (ATNM)
Actinium Pharmaceuticals Inc stock price live, this page displays NYSE ATNM stock exchange data. View the ATNM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Actinium Pharmaceuticals Inc real time stock price chart below.
What Is the Actinium Pharmaceuticals Inc Stock Price Today?
The Actinium Pharmaceuticals Inc stock price today is 0.853.
What Is the Stock Symbol for Actinium Pharmaceuticals Inc?
The stock symbol for Actinium Pharmaceuticals Inc is "ATNM."
What Stock Exchange Does Actinium Pharmaceuticals Inc Trade On?
Actinium Pharmaceuticals Inc is listed and trades on the NYSE stock exchange.
Is Actinium Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Actinium Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATNM quote. (ISIN: US00507W2061)
What Is the Actinium Pharmaceuticals Inc Stock Price Today?
The Actinium Pharmaceuticals Inc stock price today is 0.853.
What Is the Stock Symbol for Actinium Pharmaceuticals Inc?
The stock symbol for Actinium Pharmaceuticals Inc is "ATNM."
What Stock Exchange Does Actinium Pharmaceuticals Inc Trade On?
Actinium Pharmaceuticals Inc is listed and trades on the NYSE stock exchange.
Is Actinium Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Actinium Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATNM quote. (ISIN: US00507W2061)
0.853
-0.001(-0.14%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.850
0.860
52 wk Range
0.807
1.806
Earnings results expected in 6 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8500.860
52 wk Range
0.8071.806
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATNM Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
5.000
Upside
+486.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.000
(+486.17% Upside)
Actinium Pharmaceuticals Inc SWOT Analysis
Iomab-ACT's Potential | Actinium's flagship product, Iomab-ACT, shows promise in targeted cancer therapies and bone marrow transplant conditioning, with recent FDA clearance for sickle cell disease |
Market Expansion | Delve into Actinium's strategic move into the sickle cell disease market, potentially addressing 100,000 U.S. patients annually and positioning for gene therapy applications |
Financial Discipline | Explore how Actinium's efficient cost management and lower-than-expected operating expenses are extending its runway and enhancing flexibility in clinical program pursuits |
Analyst Outlook | Discover varied analyst perspectives, with price targets ranging from $21 to $50, reflecting optimism about Actinium's innovative approach in targeted radiotherapies |
Earnings
Latest Release
May 11, 2026
EPS / Forecast
-0.18 / -0.22
Revenue / Forecast
-- / --
Compare ATNM to Peers and Sector
Metrics to compare | ATNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.1x | −9.0x | −0.4x | |
PEG Ratio | −0.02 | 0.04 | 0.00 | |
Price/Book | 11.6x | 4.0x | 2.6x | |
Price / LTM Sales | 297.7x | 2.7x | 2.9x | |
Upside (Analyst Target) | - | 142.6% | 56.8% | |
Fair Value Upside | Unlock | −12.4% | 8.9% | Unlock |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Actinium Pharmaceuticals (ATNM) Stock Price Today?
The Actinium Pharmaceuticals stock price today is 0.853 USD.
What Stock Exchange Does Actinium Pharmaceuticals Trade On?
Actinium Pharmaceuticals is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Actinium Pharmaceuticals?
The stock symbol for Actinium Pharmaceuticals is "ATNM."
What Is the Actinium Pharmaceuticals Market Cap?
As of today, Actinium Pharmaceuticals market cap is 26.790M USD.
What Is Actinium Pharmaceuticals's Earnings Per Share (TTM)?
The Actinium Pharmaceuticals EPS (TTM) is -0.752.
When Is the Next Actinium Pharmaceuticals Earnings Date?
Actinium Pharmaceuticals will release its next earnings report on Aug 03, 2026.
From a Technical Analysis Perspective, Is ATNM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Actinium Pharmaceuticals Stock Split?
Actinium Pharmaceuticals has split 1 times.
How Many Employees Does Actinium Pharmaceuticals Have?
Actinium Pharmaceuticals has 25 employees.
What is the current trading status of Actinium Pharmaceuticals (ATNM)?
As of Jul 28, 2026, Actinium Pharmaceuticals (ATNM) is trading at a price of 0.853 USD, with a previous close of 0.854 USD. The stock has fluctuated within a day range of 0.850 USD to 0.860 USD, while its 52-week range spans from 0.807 USD to 1.806 USD.
What Is Actinium Pharmaceuticals (ATNM) Price Target According to Analysts?
The average 12-month price target for Actinium Pharmaceuticals is 5.000 USD, with a high estimate of 9 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +486.17% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.